CatalYm raises $150 million to tackle cancer therapy resistance
This issue of our newsletter is supported by Inpart.
On Tuesday, CatalYm added its name to the list of biotech companies surpassing $100 million in funding in a single round in 2024, as it raised $150 million in a series D round.
But what exactly is the German biotech going to use this money for?
Well, the company is working on a novel approach to tackling cancer therapy resistance.
Its lead candidate, visugromab, is a humanized monoclonal antibody that targets the tumor-produced growth differentiation factor-15 (GDF-15) – a key factor in immune resistance to cancer therapies.
With the new funds, CatalYm plans to expand the late-stage clinical development of visugromab, moving it closer to registration and potential market approval.
To find out more, read the full article: “German biotech raises $150M on its way to tackle cancer therapy resistance”
A MESSAGE FROM OUR SPONSOR INPART
Sustainable agriculture and food: R&D trends
Find out key priorities for industry-academia collaborations in sustainable food and agriculture in our brand-new R&D trends report. This data is based on exclusive insights from our partnering platform, Connect, and our most recent Global Challenge campaign seeking sustainable food and agriculture for a changing global population.
🔥 More noteworthy articles from this week:
Skeletal dysplasia, a group of genetic disorders that disrupts bone growth, affects one in 5000 babies. As treatments are intended to alleviate painful symptoms, two drugs are battling out in the clinic to prove their effectiveness.
Bioinformatics is a field of science that integrates computer technology to analyze biological data – particularly DNA and protein sequences – to advance therapies and boost healthcare research. In this article, we take a look at five companies at the top of their bioinformatics game in 2024.
The WuXi Apptec controversy triggered a fast legal response from the U.S. to protect its companies’ information from Chinese CDMOs, the BIOSECURE Act. While this bill has not become law yet, it is progressing through the legislative process, and WuXi Apptec and other “biotechnology companies of concern” are going to leave a gap in the CDMO space. But who is going to fill it?
The Canadian biotechnology industry has around 12,000 biotech organizations that employ over 200,000 people, and the number is growing year-on-year. It is expected that 65,000 new jobs in the industry will be created by 2029. In this article, we take a look at five universities in Canada that will train you to build a career in biotechnology.
Elephant endotheliotropic herpesvirus (EEHV) is the number one killer for Asian elephant calves living under managed care in North America and Europe, with a mortality rate of up to 85%. But now, biotech is coming to the rescue and an mRNA vaccine could be the solution to save these elephants from this deadly virus.
Genfit is a late-stage biopharma company taking on rare, life-threatening liver diseases with a range of therapeutic targets based on pathophysiology. The company has five assets in its portfolio, from preclinical up to phase 2. This week, Dean Hum, the chief scientific officer at Genfit, joins us on the podcast to talk about the latest in liver disease treatment.
Microbial expression systems are widely used to manufacture diagnostic and therapeutic proteins, with insulin being the best-known example. However, the commercialization success rate for new drug developments is less than 3%. Now, CDMOs are jumping in to play a key role in updating microbial expression systems, addressing limitations in existing applications, and getting ready for the manufacturing of state-of-the-art therapies.
💡Enjoying these articles? Never miss a single publication of Labiotech by becoming a part of our community! Click here to join our mailing list.